Posted On: 09/15/2014 10:00:13 AM
Post# of 94268
$GILD Company News
Gilead Sciences shares slide 2.6%
20 min ago9:39 a.m. Sept. 15, 2014
- Sue Chang
14 stocks loved by top-performing fund managers
8:29 a.m. Today8:29 a.m. Sept. 15, 2014
- Philip van Doorn
Two tech stocks with big potential
2:14 p.m. Sept. 11, 2014
- The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley
12:51 p.m. Sept. 9, 2014
- Tim Mullaney
There’s good news for speculative growth traders
2:39 p.m. Sept. 2, 2014
- The Trading Deck
Trade what you see, not what you believe
2:48 p.m. Aug. 29, 2014
- The Trading Deck
Don’t read too much into this week’s action
2:01 p.m. Aug. 26, 2014
- The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers
9:34 a.m. Aug. 25, 2014
- Tomi Kilgore
Surviving "a complex time in the market"
4:57 a.m. Aug. 25, 2014
- MarketWatch
10 S&P 500 companies growing faster than their rivals
3:29 a.m. Aug. 20, 2014
- Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates
7:27 p.m. Aug. 12, 2014
- Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices
4:17 p.m. Aug. 8, 2014
- blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug
7:32 a.m. July 25, 2014
- Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug
7:26 a.m. July 25, 2014
- Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap
4:03 p.m. July 24, 2014
- blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher
1:23 p.m. July 24, 2014
- Tom Bemis
Biotechs beat estimates, but the Street wants more
11:44 a.m. July 24, 2014
- blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love
5:39 p.m. July 23, 2014
- blogs.marketwatch.com
Updates, advisories and surprises
5:31 p.m. July 23, 2014
- MarketWatch
Facebook rallies in after hours as results top outlook
4:58 p.m. July 23, 2014
- Sue Chang
Trade-Ideas: Gilead (GILD) Is Today's Pre-Market Laggard Stock
8:52 a.m. Today8:52 a.m. Sept. 15, 2014
- TheStreet.com
Gilead to Allow Cheaper Hepatitis C Drug
7:19 a.m. Today7:19 a.m. Sept. 15, 2014
- The Wall Street Journal Interactive Edition
Gilead licenses Sovaldi to Indian firms
7:13 a.m. Today7:13 a.m. Sept. 15, 2014
- Seeking Alpha
Mylan In Pact With Gilead To Accelerate Access To Hepatitis C
5:31 a.m. Today5:31 a.m. Sept. 15, 2014
- benzinga.com
FDA tentatively approves Mylan's HIV combo
1:53 p.m. Sept. 13, 2014
- Seeking Alpha
Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog
5:25 p.m. Sept. 12, 2014
- Zacks.com
Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog
4:50 p.m. Sept. 12, 2014
- Zacks.com
Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog
4:30 p.m. Sept. 12, 2014
- Zacks.com
5 Top Stocks With Rising Earnings Estimates
7:02 a.m. Sept. 12, 2014
- Investors Business Daily
Medivation-Astellas' Xtandi's Label Expanded by FDA - Analyst Blog
6:35 p.m. Sept. 11, 2014
- Zacks.com
Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog
5:55 p.m. Sept. 11, 2014
- Zacks.com
Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog
5:45 p.m. Sept. 11, 2014
- Zacks.com
Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog
5:20 p.m. Sept. 11, 2014
- Zacks.com
Seattle Genetics-Genmab Expand Deal for Antibody Platform - Analyst Blog
5:15 p.m. Sept. 11, 2014
- Zacks.com
NPS Pharmaceuticals (NPSP) Shoots Up Ahead of FDA Panel - Analyst Blog
4:54 p.m. Sept. 11, 2014
- Zacks.com
Is This the Right Time to Buy Gilead Sciences (GILD) Stock? - Analyst Blog
4:45 p.m. Sept. 11, 2014
- Zacks.com
Medivation Eyes Blockbuster As Cancer Drug Gets An OK
4:41 p.m. Sept. 11, 2014
- Investors Business Daily
Orexigen's Obesity Drug Contrave Approved by the FDA - Analyst Blog
4:30 p.m. Sept. 11, 2014
- Zacks.com
Uncertainty Prevails For Vertex
3:48 p.m. Sept. 11, 2014
- Seeking Alpha
In A Quiet Week, Affimed Therapeutics IPO Could Garner Investor Interest
3:17 p.m. Sept. 11, 2014
- Seeking Alpha
Gilead Announces Generic Licensing Agreements to Increase Access to
Hepatitis C Treatments in Developing Countries
6:30 a.m. Today6:30 a.m. Sept. 15, 2014
- BusinessWire - BZX
Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries
6:30 a.m. Today6:30 a.m. Sept. 15, 2014
- PR Newswire - PRF
Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale
9:10 a.m. Sept. 12, 2014
- PR Newswire - PRF
Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver
9:31 a.m. Sept. 9, 2014
- PR Newswire - PRF
Global Hepatitis C Market 2014-2018
9:58 p.m. Sept. 8, 2014
- PR Newswire - PRF
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher
9:20 a.m. Sept. 4, 2014
- PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences in
September
5:00 p.m. Sept. 3, 2014
- BusinessWire - BZX
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay
9:05 a.m. Sept. 3, 2014
- PR Newswire - PRF
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard
9:10 a.m. Aug. 27, 2014
- PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver
9:31 a.m. Aug. 21, 2014
- PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana
9:20 a.m. Aug. 19, 2014
- PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health
9:10 a.m. Aug. 8, 2014
- PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver
9:31 a.m. Aug. 4, 2014
- PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis
9:20 a.m. July 31, 2014
- PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
8:40 a.m. July 31, 2014
- PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for
Broadly Neutralizing HIV Antibodies
8:00 a.m. July 30, 2014
- BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig®
(idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and
Follicular Lymphoma
7:24 a.m. July 25, 2014
- BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
10:03 a.m. July 24, 2014
- ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF)
12:30 a.m. July 24, 2014
- PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access
to Medicines in Developing World Countries
12:00 a.m. July 24, 2014
- BusinessWire - BZX
Gilead Sciences shares slide 2.6%
20 min ago9:39 a.m. Sept. 15, 2014
- Sue Chang
14 stocks loved by top-performing fund managers
8:29 a.m. Today8:29 a.m. Sept. 15, 2014
- Philip van Doorn
Two tech stocks with big potential
2:14 p.m. Sept. 11, 2014
- The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley
12:51 p.m. Sept. 9, 2014
- Tim Mullaney
There’s good news for speculative growth traders
2:39 p.m. Sept. 2, 2014
- The Trading Deck
Trade what you see, not what you believe
2:48 p.m. Aug. 29, 2014
- The Trading Deck
Don’t read too much into this week’s action
2:01 p.m. Aug. 26, 2014
- The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers
9:34 a.m. Aug. 25, 2014
- Tomi Kilgore
Surviving "a complex time in the market"
4:57 a.m. Aug. 25, 2014
- MarketWatch
10 S&P 500 companies growing faster than their rivals
3:29 a.m. Aug. 20, 2014
- Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates
7:27 p.m. Aug. 12, 2014
- Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices
4:17 p.m. Aug. 8, 2014
- blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug
7:32 a.m. July 25, 2014
- Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug
7:26 a.m. July 25, 2014
- Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap
4:03 p.m. July 24, 2014
- blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher
1:23 p.m. July 24, 2014
- Tom Bemis
Biotechs beat estimates, but the Street wants more
11:44 a.m. July 24, 2014
- blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love
5:39 p.m. July 23, 2014
- blogs.marketwatch.com
Updates, advisories and surprises
5:31 p.m. July 23, 2014
- MarketWatch
Facebook rallies in after hours as results top outlook
4:58 p.m. July 23, 2014
- Sue Chang
Trade-Ideas: Gilead (GILD) Is Today's Pre-Market Laggard Stock
8:52 a.m. Today8:52 a.m. Sept. 15, 2014
- TheStreet.com
Gilead to Allow Cheaper Hepatitis C Drug
7:19 a.m. Today7:19 a.m. Sept. 15, 2014
- The Wall Street Journal Interactive Edition
Gilead licenses Sovaldi to Indian firms
7:13 a.m. Today7:13 a.m. Sept. 15, 2014
- Seeking Alpha
Mylan In Pact With Gilead To Accelerate Access To Hepatitis C
5:31 a.m. Today5:31 a.m. Sept. 15, 2014
- benzinga.com
FDA tentatively approves Mylan's HIV combo
1:53 p.m. Sept. 13, 2014
- Seeking Alpha
Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog
5:25 p.m. Sept. 12, 2014
- Zacks.com
Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog
4:50 p.m. Sept. 12, 2014
- Zacks.com
Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog
4:30 p.m. Sept. 12, 2014
- Zacks.com
5 Top Stocks With Rising Earnings Estimates
7:02 a.m. Sept. 12, 2014
- Investors Business Daily
Medivation-Astellas' Xtandi's Label Expanded by FDA - Analyst Blog
6:35 p.m. Sept. 11, 2014
- Zacks.com
Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog
5:55 p.m. Sept. 11, 2014
- Zacks.com
Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog
5:45 p.m. Sept. 11, 2014
- Zacks.com
Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog
5:20 p.m. Sept. 11, 2014
- Zacks.com
Seattle Genetics-Genmab Expand Deal for Antibody Platform - Analyst Blog
5:15 p.m. Sept. 11, 2014
- Zacks.com
NPS Pharmaceuticals (NPSP) Shoots Up Ahead of FDA Panel - Analyst Blog
4:54 p.m. Sept. 11, 2014
- Zacks.com
Is This the Right Time to Buy Gilead Sciences (GILD) Stock? - Analyst Blog
4:45 p.m. Sept. 11, 2014
- Zacks.com
Medivation Eyes Blockbuster As Cancer Drug Gets An OK
4:41 p.m. Sept. 11, 2014
- Investors Business Daily
Orexigen's Obesity Drug Contrave Approved by the FDA - Analyst Blog
4:30 p.m. Sept. 11, 2014
- Zacks.com
Uncertainty Prevails For Vertex
3:48 p.m. Sept. 11, 2014
- Seeking Alpha
In A Quiet Week, Affimed Therapeutics IPO Could Garner Investor Interest
3:17 p.m. Sept. 11, 2014
- Seeking Alpha
Gilead Announces Generic Licensing Agreements to Increase Access to
Hepatitis C Treatments in Developing Countries
6:30 a.m. Today6:30 a.m. Sept. 15, 2014
- BusinessWire - BZX
Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries
6:30 a.m. Today6:30 a.m. Sept. 15, 2014
- PR Newswire - PRF
Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale
9:10 a.m. Sept. 12, 2014
- PR Newswire - PRF
Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver
9:31 a.m. Sept. 9, 2014
- PR Newswire - PRF
Global Hepatitis C Market 2014-2018
9:58 p.m. Sept. 8, 2014
- PR Newswire - PRF
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher
9:20 a.m. Sept. 4, 2014
- PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences in
September
5:00 p.m. Sept. 3, 2014
- BusinessWire - BZX
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay
9:05 a.m. Sept. 3, 2014
- PR Newswire - PRF
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard
9:10 a.m. Aug. 27, 2014
- PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver
9:31 a.m. Aug. 21, 2014
- PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana
9:20 a.m. Aug. 19, 2014
- PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health
9:10 a.m. Aug. 8, 2014
- PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver
9:31 a.m. Aug. 4, 2014
- PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis
9:20 a.m. July 31, 2014
- PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
8:40 a.m. July 31, 2014
- PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for
Broadly Neutralizing HIV Antibodies
8:00 a.m. July 30, 2014
- BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig®
(idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and
Follicular Lymphoma
7:24 a.m. July 25, 2014
- BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
10:03 a.m. July 24, 2014
- ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF)
12:30 a.m. July 24, 2014
- PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access
to Medicines in Developing World Countries
12:00 a.m. July 24, 2014
- BusinessWire - BZX
(0)
(0)
